Sarcopenia Market Anticipates Impressive Growth Trajectory Across 7MM During the Study Period (2020–2034) | DelveInsight

New York, USA, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sarcopenia Market Anticipates Impressive Growth Trajectory Across 7MM During the Study Period (2020–2034) | DelveInsight The sarcopenia market size shall grow during the forecast period (2024–2034) due to the launch of upcoming therapies and the increasing cases of sarcopenia. This sarcopenia treatment market is expected to increase at a significant rate.DelveInsight's Sarcopenia Market Insights report includes a comprehensive understanding of current treatment practices, sarcopenia emerging drugs, market share of individual therapies, and current and forecasted sarcopenia market size from 2020 to 2034, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].Key Takeaways from the Sarcopenia Market ReportAccording to DelveInsight's analysis, sarcopenia market size in the 7MM is expected to grow at a significant CAGR by 2034.The total diagnosed prevalent cases of sarcopenia in the 7MM was 27.4 million cases in 2023 and this number is forecasted to climb at a significant CAGR in the research period (2020–2034).Prominent sarcopenia companies working in the domain, including Biophytis, MyMD Pharmaceuticals, Inc., and others, are actively working on innovative drugs for sarcopenia. These novel sarcopenia therapies are anticipated to enter the sarcopenia market in the forecast period and are expected to change the market.Some of the key therapies for sarcopenia treatment include Sarconeos (BIO101), MYMD-1, and others. In August 2024, TNF Pharmaceuticals, Inc. announced plans to move forward with its lead program, MYMD-1, into fully funded mid-stage clinical trials. The upcoming studies will further investigate the drug's effectiveness in treating sarcopenia/frailty, following statistically significant positive outcomes from a previous Phase II trial.Discover which therapies are expected to grab sarcopenia market share @ Sarcopenia Treatment Market ReportSarcopenia OverviewSarcopenia is a condition marked by a gradual decline in muscle mass, strength, and function, commonly linked to aging. It arises from a combination of physiological changes in the musculoskeletal system as people grow older. This condition is a major health issue due to its effects on physical performance, functional abilities, and overall health.Sarcopenia stems from a mix of genetic factors, lifestyle habits, and age-related physiological changes, primarily involving reduced muscle mass and function. Hormonal changes, such as decreased levels of growth hormone, testosterone, and insulin-like growth factor 1, play a role in its progression. Factors like lack of physical activity, inadequate exercise, and poor nutrition accelerate muscle loss. Other contributing elements include chronic diseases, inflammation, neuromuscular issues, genetics, certain medications, hormonal imbalances, malabsorption, smoking, and excessive alcohol consumption.Sarcopenia diagnosis requires various methods, including DEXA scans, anthropometry, MRI, and CT scans to assess muscle mass, as well as tests for grip strength, gait speed, and blood analyses for additional insights. However, establishing precise diagnostic criteria is complex due to differing measurement techniques and their intricacies.Sarcopenia Epidemiology SegmentationThe sarcopenia epidemiology section provides insights into the historical and current sarcopenia patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.The sarcopenia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:Total Diagnosed Sarcopenia Prevalence Gender-specific Diagnosed Sarcopenia PrevalenceAge-specific Diagnosed Sarcopenia Prevalence Severity-specific Diagnosed Sarcopenia Prevalence Download the report to understand which factors are driving sarcopenia epidemiology trends @ Sarcopenia Epidemiological InsightsSarcopenia Treatment Market As of now, there are no approved pharmacological treatments for sarcopenia. Consequently, the current recommendations for preventing and treating sarcopenia primarily focus on lifestyle changes. This underscores a notable gap in available treatments and highlights the urgent need for developing safe and effective therapies to address the issues faced by those with sarcopenia.To manage hormonal imbalances and support overall musculoskeletal health, adequate protein intake, proper nutrition, vitamin D supplements, and sometimes hormone replacement therapy may be recommended by healthcare professionals. Although nutritional supplements can be beneficial, steroid hormones like dehydroepiandrosterone (DHEA), testosterone, and anabolic steroids have shown some positive effects, but their use is restricted due to potential adverse effects.Although no specific drugs have been approved for sarcopenia, research is ongoing to explore potential pharmacological treatments. Medications such as selective androgen receptor modulators (SARMs) and myostatin inhibitors are being studied for their potential to enhance muscle growth and function.Not everyone with sarcopenia will also experience sarcopenic obesity, although these conditions can occur together, particularly in older adults. The relationship between sarcopenia and obesity is complex, and the frequency of sarcopenic obesity varies across different populations. Some research suggests that obesity might increase the risk of developing sarcopenia.Sarcopenic obesity, characterized by the combination of muscle loss and excess body fat, presents a distinctive challenge in treatment. The interaction between muscle depletion and increased fat can lead to greater risks of functional decline and metabolic problems. Managing this condition requires a comprehensive approach that focuses on both maintaining or restoring muscle mass and reducing excess body fat. Effective management typically involves customized exercise regimens and dietary strategies, aiming for a holistic intervention to enhance overall health.Learn more about the FDA-approved drugs in sarcopenia therapeutics market @ Drugs for Sarcopenia Treatment Emerging Sarcopenia Drugs and CompaniesThere are many innovative key sarcopenia companies involved in the development of promising products such as Biophytis (Sarconeos), MyMD Pharmaceuticals, Inc. (MYMD-1), and others.Biophytis is developing Sarconeos (BIO101), an orally administered small molecule designed to treat neuromuscular diseases. By activating the MAS receptor in muscle cells, Sarconeos boosts biological resilience and helps maintain muscle function in conditions related to aging and muscle wasting. The MAS receptor plays a key role in the Renin-Angiotensin System, ...Full story available on Benzinga.com